Home / Business and Economy / Avanzanite Licenses Zemcelpro for Rare Blood Cancers
Avanzanite Licenses Zemcelpro for Rare Blood Cancers
9 Nov
Summary
- Avanzanite secures EU commercialisation rights for Zemcelpro.
- Zemcelpro treats adults with blood cancers lacking other donor options.
- Avanzanite will support a planned Phase 3 trial for Zemcelpro.
Avanzanite Bioscience announced an exclusive license agreement with ExCellThera for the commercialization of Zemcelpro. This therapy is authorized in the European Union for adult patients with hematological malignancies requiring an allogeneic hematopoietic stem cell transplant when no other suitable donor cells are available.
The agreement grants Avanzanite commercialization rights across 32 countries, including the European Economic Area, UK, and Switzerland. Avanzanite will assume the role of the EU marketing authorization holder and plans to submit applications in the UK and Switzerland.
ExCellThera will continue to manage manufacturing and supply, while also leading global development for potential indication expansions. Avanzanite will contribute to a planned Phase 3 trial assessing Zemcelpro against alternative transplant options for high-risk leukemias and myelodysplastic syndromes.
Zemcelpro is an allogeneic hematopoietic stem cell therapy. It utilizes expanded CD34+ hematopoietic stem cells and unexpanded CD34-cells to support immune reconstitution and provide graft-versus-leukemia effects post-transplantation.
This partnership marks Avanzanite's fifth rare disease launch and first advanced therapy medicinal product. The company, founded in 2022, aims to become a leading European rare disease pharmaceutical company.
